Barclays PLC Dia Medica Therapeutics Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 27,726 shares of DMAC stock, worth $172,732. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,726Holding current value
$172,732% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding DMAC
# of Institutions
45Shares Held
4.64MCall Options Held
8.2KPut Options Held
200-
Vanguard Group Inc Valley Forge, PA1.24MShares$7.74 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$5.23 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX515KShares$3.21 Million6.41% of portfolio
-
Bleichroeder LP New York, NY382KShares$2.38 Million0.54% of portfolio
-
Geode Capital Management, LLC Boston, MA306KShares$1.9 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $165M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...